Vascular endothelial growth factor (VEGF) is a proangiogenic factor that plays a key role in the pathogenesis of neovascular age-related macular dengeneration (AMD). Elevated levels of the VEGF~165~ isoform lead to the development of choroidal neovascularization (CNV), the growth of fragile, new vessels in the macula that may cause exudation, and hemorrhages. Pegaptanib sodium (Macugen^®^, \[OSI\] Eyetech Pharmaceuticals, Pfizer) blocks the extracellular VEGF~165~ isoform and inhibits its binding to the VEGF receptors. This action prevents the increased vascular permeability and choroidal neovascularization that is associated with neovascular AMD.

Efficacy
========

The results of the VEGF Inhibition Study In Ocular Neovascularization (VISION) have shown that pegaptanib sodium confers statistically significant, and clinically meaningful, benefit in the treatment of all angiographic subtypes of neovascular AMD ([@b5-co-2-485]; [@b4-co-2-485]). The trials randomized patients to receive pegaptanib sodium 0.3 mg, 1.0 mg, or 3.0 mg intravitreal (ITV) injections or sham injections every 6 weeks. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity (VA) at 54 weeks. This was achieved in 70% of patients receiving 0.3 mg pegaptanib sodium, regardless of photodynamic therapy (PDT), compared with 55% in the placebo patient group (p \< 0.001). No additional benefits, in terms of clinical efficacy or safety, were measured in the 1.0 mg and 3.0 mg patient groups compared with those receiving the lower 0.3 mg dose.

During the second year of the study, mean VA was stabilized in patients receiving 0.3 mg pegaptanib sodium, while those receiving placebo injections experienced continued vision loss. At year 2, change in vision (recorded as letters observed) was approximately 50% better in patients receiving 0.3 mg pegaptanib sodium than in those receiving placebo injections, irrespective of CNV lesion subtype ([@b2-co-2-485]).

On the basis of these findings, pegaptanib sodium has been approved at a recommended dosage of 0.3 mg, administered as an ITV injection every 6 weeks, for the treatment of neovascular AMD.

The results of VISION appear less encouraging than those recorded in the early ranibizumab clinical trials -- the ANti-VEGF antibody for the treatment of predominantly classic CHORoidal neovascularization in AMD (ANCHOR) trial and the Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular AMD (MARINA) ([@b1-co-2-485]; [@b9-co-2-485], [@b10-co-2-485]). However, it is important to consider differences in the patient populations recruited for the studies: MARINA recruited patients with minimally classic or occult lesions with no classic CNV, and ANCHOR recruited patients with predominantly classic CNV lesions. VISION, however, enrolled patients with all neovascular AMD lesion subtypes (25% predominantly classic, 39% occult with no classic and 36% minimally classic).

Safety
======

Pegaptanib sodium has a favorable safety profile after 1 and 2 years of continuous treatment. The 2-year safety results demonstrated that all doses of pegaptanib were well tolerated et al ([@b3-co-2-485]). The most common ocular adverse events were transient, mild to moderate in intensity, and attributed to the injection preparation and procedure. In year 1, serious injection-related complications included endophthalmitis (at a rate of 0.16% per injection). Most of the cases resulted from violations of the injection preparation protocol and the rate dropped to 0.07% in the second year after reinforced aseptic procedure. In general, systemic adverse events were relatively low and similar in the pegaptanib sodium and placebo patient groups ([@b3-co-2-485]).

Retrospective analysis
======================

[@b7-co-2-485] determined that the treatment benefits afforded by pegaptanib sodium are due to its disease modifying effect, an analysis of which has been proposed by [@b11-co-2-485] and by [@b6-co-2-485]. The authors of the aforementioned papers analyzed data from the second year of VISION. After the initial 54-week treatment period, patients were re-randomized to either continue or discontinue treatment (in an unmasked fashion) for a further 48 weeks. The authors found that visual outcomes in patients who were randomized to discontinue treatment after 54 weeks and who were followed for a further 48 weeks, were significantly different to those in patients receiving placebo injections in terms of loss of 15 letters of vision (relative risk \[RR\] 0.70, 95% confidence interval \[CI\] 0.57--0.88; p = 0.002), indicating that the treatment had a modifying effect on the disease ([@b7-co-2-485]).

In the post hoc analysis of VISION, the treatment benefit seen in patients receiving 0.3 mg pegaptanib sodium was particularly marked in those with early lesions; 80% of those with early lesions achieved the primary end point of \<15 letters lost. In addition, nearly half (47%) of patients with early lesions maintained VA when treated with 0.3 mg pegaptanib sodium, and 20% of these patients gained ≥15 letters of vision ([@b4-co-2-485]).

Clinical practice
=================

In our clinical centre, we treated 45 eyes (in 45 patients) with pegaptanib sodium, between June 2006 and June 2007. The lesion subtypes treated were: classic lesions in 5 eyes, minimally classic lesions in 7 eyes, and occult lesions in 33 eyes. Of these patients, 22 were followed for 18 weeks.

From our own clinical experience of treating all neovascular AMD lesion subtypes with pegaptanib sodium, the efficacy of the agent differs when comparing treatment outcomes in patients with early lesions and those with established lesions. In our department it has been observed that pegaptanib sodium treatment in early lesions results in better outcomes than in established lesions. This is particularly true in patients with previously untreated minimally classic and occult lesions in whom VA improvement and lesion size stabilization has been recorded. These results are very important and contrast with the relatively moderate treatment effects seen in minimally classic and occult lesion after PDT.

In our patients, a frequent discrepancy was also observed between anatomic factors, examined with fluorescein angiography (FAG) and indocyanine green angiography (ICGA), and functional factors: VA improvement is often not correlated with lesion size changes in FAG+ICGA. Our observations have also led us to conclude that pegaptanib sodium has a slower mode of action compared with that of unselective VEGF inhibitors. Clinical experience would suggest that, because pegaptanib sodium's mode of action is slower, at least 3 ITV injections are required to produce good efficacy.

In a recent study, Quiran et al evaluated the efficacy of pegaptanib sodium as primary therapy in 90 patients with naive lesions (80% occult, 13% minimally classic, and 7% predominantly classic) (Quiran et al 2007). All patients were injected with 0.3 mg of ITV pegaptanib sodium at 6-week intervals. FAG and OCT were carried out at baseline and were repeated after 3 treatments, whereafter an additional ITV injection of pegaptanib sodium was administered if the CNV was observed to be active. A response rate of 90% was recorded with: 20% of patients gaining ≥3 lines of vision; vision stabilization being achieved in 70% of patients, and a loss of ≥3 lines being recorded in 10% of patients. An average of 3.5 injections were administered in those patients who experienced a gain in vision of ≥3 lines.

Our experience echoes the findings of Quiran et al in that we also found 3--4 injections to be enough to stabilize the lesion size and to either stabilize or improve VA in the majority of patients with early lesions. One occult lesion treated with pegaptanib sodium is described in the following case study.

An 82-year-old woman was referred to our department after a loss of VA in her right eye (RE). Best corrected VA (BCVA) was 10/20 in her RE and 18/20 in her left eye. Biomiscropy of the anterior segment was unremarkable in both eyes. FAG+ICGA and OCT revealed an occult CNV membrane associated with neovascular AMD in the RE (see [Figure 1](#f1-co-2-485){ref-type="fig"}). The patient was treated with 5 ITV injections of of pegaptanib sodium given 6-weekly.

FAG+ICGA and OCT were performed before every injection. The patient's RE VA stabilized after 2 injections and FA+ICGA showed an increase in lesion leakage. At follow-up after the third injection, VA in the RE had improved (16/20) and the lesion size was stable (as assessed with either with FAG+ICGA and OCT). One month after the fifth ITV injection, both VA and lesion size were stable and treatment was stopped. At follow-up 9 months after last injection, BCVA was 16/20 and FAG+ICGA and OCT showed an absence of lesion activity (see [Figure 1](#f1-co-2-485){ref-type="fig"}).

Stable VA is commonly seen after initial injections with selective anti-VEGF treatment, but lesion activity often persists on angiography. As the above clinical case exemplifies, however, VA and the angiographic pattern in the discussed patient were stable after only 2 injections of pegaptanib sodium and the beneficial effects of treatment were evident after only 3 treatments.

From our clinical experience, we conclude that at this time pegaptanib sodium has good efficacy and safety profiles and represents a good treatment option for patients with early CNV membranes associated with neovascular AMD.
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